DNA Script is the world’s leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims at accelerating innovation in life sciences and technology through rapid, affordable, and high-quality DNA synthesis. DNA Script’s approach leverages nature's billions of years of evolution in synthesizing DNA to enable genome scale synthesis.

The Company’s technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemicals production, improved crops as well as data storage.


Team Member
more about
Christian Uhrich
Latest News Entry
DNA Script Launches Early Access Program for Latest Advancements to the SYNTAX Platform and Enzymatic DNA Synthesis Technology

Program participants receive early access to the upcoming release of kits designed to print longer oligos and enable labeling with fluorophores, quenchers, and biotin

DNA Script Partners with Asia-Pacific Distributors as Part of Global Expansion to Meet Demand for Same-day Enzymatic DNA Synthesis

DNA Script expands worldwide footprint to China, Hong Kong, India, Singapore, South Korea and Taiwan for sales, distribution, and support of enzymatic synthesis products

DNA Script Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2022

DNA Script’s enzymatic DNA printing on demand technology recognized as no. 3 in the biotech category

DNA Script Joins Wellcome Leap R3 Program to Advance RNA Products and Therapies

Multi-year, multi-million dollar collaboration will develop new tools to rapidly accelerate the development of RNA-based products, catalyzing a new era in healthcare

DNA Script Obtains CE Mark for SYNTAX DNA Printing Platform

DNA Script, a leader in Enzymatic DNA Synthesis (EDS), announced the CE marking of its SYNTAX System, the first EDS-powered benchtop DNA printer

DNA Script Raises $165M in Oversubscribed Series C Financing to Accelerate Commercialization of Enzymatic DNA Printing Platform

New Funding, Targeted to Accelerate Application Expansion and Platform Commercialization, Brings Total Amount Raised to Date to $280M

DNA Script Expands Series B to $89M

Casdin Capital leads the $50M extension; funding will support commercial launch of SYNTAX™️ — the world’s first enzymatic DNA printer.

DNA Script Raises $38.5 Million in Series B Financing

Oversubscribed round led by LSP will fund accelerated product development and commercial operations in the U.S.

M Ventures participates in DNA Script' Successful Series A Fundraising of €11 M to Advance Development of its DNA Synthesis Technology

Paris, September 12th, 2017. Synthetic DNA manufacturer DNA Script has today announced a Series A fundraising of 11 million euros ($13 million) led by Illumina Ventures, with additional investments from M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany, plus existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners.

all related news
all portfolio news